EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study

Toshiyuki Yamamoto, Hideaki Tanizaki, Kenshi Yamasaki, Naoko Matsubara, Masahiko Nakayama, Eri Iwashita, Keiichi Yamanaka

Dermatology and Therapy · 2026-06 · 16 (6) · 3167-3188

DOI: 10.1007/s13555-026-01772-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology and Therapy, online erschienen am 10.05.2026. Verfasst von Toshiyuki Yamamoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Fukushima Medical University, Fukushima, Japan. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie GK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

AdalimumabHumiraPostmarketing surveillancePyoderma gangrenosumReal-world evidenceSafetySteroidSubtypeTNF-α inhibitor

Autor:innen und Institutionen

  • Department of Dermatology, Fukushima Medical University, Fukushima, Japan.
  • Department of Dermatology, Kansai Medical University, Hirakata, Japan.
  • Department of Dermatology, Tohoku University, Sendai, Japan.
  • ALOOP CLINIC and LAB, Tokyo, Japan.
  • Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo, 108-0023, Japan. naoko.matsubara@abbvie.com.
  • Medical, AbbVie GK, 3-1-21 Shibaura, Minato-ku, Tokyo, 108-0023, Japan.

Förderung

  • AbbVie GK

Zitieren

APA

Yamamoto, T., Tanizaki, H., Yamasaki, K., Matsubara, N., Nakayama, M., Iwashita, E., & Yamanaka, K. (2026). Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study. Dermatology and Therapy, 16(6), 3167-3188. https://doi.org/10.1007/s13555-026-01772-4

Vancouver

Yamamoto T, Tanizaki H, Yamasaki K, Matsubara N, Nakayama M, Iwashita E, et al. Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study. Dermatology and Therapy. 2026;16(6):3167-3188. doi:10.1007/s13555-026-01772-4

BibTeX
@article{Yamamoto2026,
  author = {Yamamoto, Toshiyuki and Tanizaki, Hideaki and Yamasaki, Kenshi and Matsubara, Naoko and Nakayama, Masahiko and Iwashita, Eri and Yamanaka, Keiichi},
  title = {Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study},
  journal = {Dermatology and Therapy},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {3167--3188},
  doi = {10.1007/s13555-026-01772-4}
}
Kostenlos starten →